By 2010, a total of 3 830 932 second
doses of monovalent RVA vaccine had
been administered to the National Centre
for Child and Adolescent Health’s
target population of 4 677 341 children
younger than 5 years. This was equal to
a national two-dose coverage of 82%
(Table 1). Two-dose coverage was at
least 69% across all the age groups and
socioeconomic categories that we considered
(Table 1). In general, coverage
was relatively higher among children
younger than 24 months and in the
states with high or intermediate socioeconomic
status.